What is Protara Therapeutics, Inc.'s earnings per share (EPS)?

Protara Therapeutics, Inc. (TARA) reported diluted earnings per share of -$1.34 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Protara Therapeutics, Inc. (TARA) Financials

TARA

FY2025 annual

Net Income -$57.4M -28.7% YoY

EPS (Diluted) -$1.34 YoY not available

Free Cash Flow -$56.5M -57.4% YoY

Operating Cash Flow -$56.4M -57.4% YoY

Market Cap $162.8M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.0x on $161.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TARA SEC filings page.

This page shows Protara Therapeutics, Inc. (TARA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TARA FY2025 2026-10-04

Protara operates as a development-stage biotech, using outside financing to fund rising research costs while losses increasingly convert directly into cash outflows.

Earnings quality is straightforward but worsening in scale: FY2025 net loss was $57.4M, operating cash flow was -$56.4M, and free cash flow was -$56.5M. Because these measures remain tightly aligned, reported losses are translating into cash consumption rather than being mainly accounting effects; compared with FY2024, the larger gap is the magnitude of spending, not a change in conversion.

Research investment is accelerating faster than administrative spending: R&D rose from $31.7M in FY2024 to $42.6M in FY2025, while SG&A increased from $17.5M to $21.9M. That mix pushed operating losses from $49.2M to $64.5M, indicating that development activity—not overhead alone—is driving the higher cash requirement.

The balance sheet is funded more by equity than debt: FY2025 financing cash flow of $82.7M helped support $209.5M of assets despite the annual operating outflow, while debt-to-equity remained only 0.1x. Shares outstanding rose to 54.1M from 36.8M in FY2024, linking the stronger asset base to substantial equity issuance; reported liquidity equaled 42.1 months of FY2025 operating outflow at year-end.

Financial Health Signals

Financial health score not available

Protara Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Protara Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Protara Therapeutics, Inc. reported a net loss of $57.4M while operations used $56.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$23.3M

YoY-41.0%

QoQ-19.0%

Protara Therapeutics, Inc.'s EBITDA was -$23.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 41.0% from the same quarter a year earlier. Against the prior quarter it is down 19.0%.

Net Income

-$21.7M

YoY-44.8%

QoQ-21.9%

Protara Therapeutics, Inc. reported -$21.7M in net income in Q2 2026. This represents a decrease of 44.8% from the same quarter a year earlier. Against the prior quarter it is down 21.9%.

EPS (Diluted)

-$0.36

YoY-2.9%

QoQ-16.1%

Protara Therapeutics, Inc. earned -$0.36 per diluted share (EPS) in Q2 2026. This represents a decrease of 2.9% from the same quarter a year earlier. Against the prior quarter it is down 16.1%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$17.1M

YoY-45.8%

QoQ+15.9%

5Y CAGR-18.3%

10Y CAGR-6.7%

Protara Therapeutics, Inc. held $17.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

59M

YoY+53.2%

QoQ+5.1%

5Y CAGR+39.4%

10Y CAGR+13.6%

Protara Therapeutics, Inc. had 59M shares outstanding in Q2 2026. This represents an increase of 53.2% from the same quarter a year earlier. Against the prior quarter it is up 5.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-13.4%

YoY-3.1pp

QoQ-3.6pp

Protara Therapeutics, Inc.'s ROE was -13.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.6 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$17.0M

YoY+57.4%

QoQ+25.0%

Protara Therapeutics, Inc. invested $17.0M in research and development in Q2 2026. This represents an increase of 57.4% from the same quarter a year earlier. Against the prior quarter it is up 25.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TARA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TARA quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.9M	N/A	N/A
R&D Expenses	N/A	$42.6M+34.5%	$31.7M+26.9%	$25.0M+48.7%	$16.8M-20.3%	$21.1M+76.0%	$12.0M+209.0%	$3.9M-67.3%	$11.8M-45.4%	$21.7M+14.9%	$18.9M+52.4%	$12.4M+92.5%	$6.4M+61.0%	$4.0M-32.4%	$5.9M
SG&A Expenses	N/A	$21.9M+25.6%	$17.4M-6.3%	$18.6M-10.2%	$20.7M-21.5%	$26.4M+17.5%	$22.5M+468.4%	$4.0M-58.5%	$9.5M+9.8%	$8.7M-11.8%	$9.8M+15.9%	$8.5M+107.3%	$4.1M+30.9%	$3.1M+49.7%	$2.1M
Operating Income	N/A	-$64.5M-31.3%	-$49.2M-12.7%	-$43.6M+35.0%	-$67.1M-41.2%	-$47.5M-37.9%	-$34.4M	N/A	-$21.4M+29.6%	-$30.4M-5.8%	-$28.7M-37.5%	-$20.9M-175.3%	-$7.6M-6.4%	-$7.1M+10.9%	-$8.0M
EBITDA	N/A	-$64.2M-31.5%	-$48.8M-12.8%	-$43.3M+35.2%	-$66.8M-41.0%	-$47.4M-37.9%	-$34.3M	N/A	-$21.3M+29.6%	-$30.2M-5.7%	-$28.6M-37.3%	-$20.8M-175.7%	-$7.5M-6.4%	-$7.1M+10.6%	-$7.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$34K	N/A	N/A	N/A	N/A	N/A	$857K-0.5%	$861K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$110K-219.6%	$92K+165.7%	-$140K
Net Income	N/A	-$57.4M-28.7%	-$44.6M-10.4%	-$40.4M+38.7%	-$66.0M-39.6%	-$47.3M-39.1%	-$34.0M	N/A	-$20.7M+30.8%	-$30.0M-5.0%	-$28.5M-33.4%	-$21.4M-539.6%	-$3.3M+57.8%	-$7.9M+0.7%	-$8.0M
EPS (Basic)	N/A	-$1.34+38.2%	-$2.17+39.2%	-$3.57+39.1%	-$5.86-39.2%	-$4.21	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.34	-$2.17	-$3.57+39.1%	-$5.86-39.2%	-$4.21	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	43M	21M	11M+0.6%	11M+0.2%	11M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$17.0M+57.4%	$13.6M+48.3%	N/A	$9.6M+18.8%	$10.8M+68.6%	$9.1M+18.1%	N/A	$8.1M+29.8%
SG&A Expenses	$6.4M+9.5%	$6.1M+21.9%	N/A	$5.2M+21.3%	$5.8M+36.1%	$5.0M+21.3%	N/A	$4.3M-5.0%
Operating Income	-$23.3M-40.6%	-$19.6M-39.0%	N/A	-$14.8M-19.7%	-$16.6M-55.6%	-$14.1M-19.2%	N/A	-$12.3M-15.2%
EBITDA	-$23.3M-41.0%	-$19.5M-39.2%	N/A	-$14.7M-19.8%	-$16.5M-55.9%	-$14.0M-19.3%	N/A	-$12.2M-15.3%
Interest Expense	$1.5M+21.0%	N/A	N/A	N/A	$1.2M	N/A	N/A	N/A
Net Income	-$21.7M-44.8%	-$17.8M-49.3%	N/A	-$13.3M-18.2%	-$15.0M-57.3%	-$11.9M-7.4%	N/A	-$11.2M-13.8%
EPS (Basic)	-$0.36-2.9%	-$0.31-6.9%	-$0.38+11.6%	-$0.31+38.0%	-$0.35+22.2%	-$0.29+70.1%	-$0.43+52.2%	-$0.50+42.5%
EPS (Diluted)	-$0.36-2.9%	-$0.31-6.9%	-$0.38+11.6%	-$0.31	-$0.35	-$0.29	-$0.43	-$0.50
Diluted Shares (Avg)	61M+44.3%	58M+41.3%	N/A	42M	42M	41M	N/A	22M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

TARA Balance Sheet

TARA quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$209.5M+15.4%	$181.5M+129.8%	$79.0M-30.3%	$113.3M-34.4%	$172.6M-15.0%	$203.2M+16511.4%	$1.2M-94.8%	$23.5M-46.5%	$44.0M+1.1%	$43.5M-35.6%	$67.5M-20.4%	$84.8M+1398.5%	$5.7M	N/A
Current Assets	$159.5M-7.3%	$172.2M+150.6%	$68.7M-20.2%	$86.1M-7.5%	$93.1M-45.0%	$169.4M+22077.4%	$764K-96.7%	$23.2M-46.6%	$43.5M+1.7%	$42.8M-35.8%	$66.6M-21.3%	$84.6M+1487.3%	$5.3M	N/A
Cash & Equivalents	$49.7M-69.5%	$162.8M+311.3%	$39.6M+64.1%	$24.1M-32.5%	$35.7M-78.8%	$168.6M+29793.3%	$564K-97.1%	$19.4M-8.5%	$21.2M-41.8%	$36.4M-9.1%	$40.0M-41.8%	$68.8M+2364.7%	$2.8M+15.9%	$2.4M
Short-Term Investments	$105.9M+1313.1%	$7.5M-71.2%	$26.0M-56.9%	$60.2M+8.5%	$55.5M	$0	$0-100.0%	$2.5M-88.1%	$21.0M+325.8%	$4.9M-80.5%	$25.2M+71.0%	$14.8M+525.5%	$2.4M	$0
Long-Term Investments	$42.3M	$0	$0-100.0%	$17.9M-54.7%	$39.5M	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	$29.5M0.0%	$29.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.1M-8.8%	$14.3M+34.7%	$10.6M-5.1%	$11.2M+4.9%	$10.7M+172.9%	$3.9M+16.8%	$3.4M-82.1%	$18.7M+102.8%	$9.2M+81.9%	$5.1M+22.9%	$4.1M+76.8%	$2.3M-97.8%	$106.2M	N/A
Current Liabilities	$10.9M-0.2%	$11.0M+78.3%	$6.1M+7.1%	$5.7M+33.6%	$4.3M+47.4%	$2.9M-13.0%	$3.4M+8.9%	$3.1M-66.7%	$9.2M+81.9%	$5.1M+22.9%	$4.1M+76.8%	$2.3M-76.1%	$9.8M	N/A
Non-Current Liabilities	$2.1M-37.0%	$3.4M-25.1%	$4.5M-18.0%	$5.5M-14.4%	$6.4M+539.0%	$999K	$0-100.0%	$15.7M	$0	$0	$0	$0-100.0%	$96.4M	N/A
Total Equity	$196.4M+17.5%	$167.1M+144.6%	$68.3M-33.1%	$102.1M-37.0%	$161.9M-18.7%	$199.2M+9462.9%	-$2.1M-144.5%	$4.8M-86.2%	$34.7M-9.6%	$38.4M-39.4%	$63.4M-23.1%	$82.5M+182.0%	-$100.5M-16.0%	-$86.7M
Retained Earnings	-$302.4M-23.4%	-$245.0M-22.3%	-$200.4M-25.3%	-$160.0M-70.2%	-$94.0M-101.1%	-$46.8M-265.8%	-$12.8M+93.9%	-$210.5M-10.9%	-$189.7M-18.8%	-$159.8M-21.7%	-$131.3M-19.5%	-$109.9M-9.3%	-$100.5M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$176.1M+12.2%	$191.9M+13.9%	$209.5M+15.4%	$144.6M+53.7%	$156.9M+54.4%	$168.6M+147.4%	$181.5M+129.8%	$94.1M+6.4%
Current Assets	$146.2M+16.8%	$140.0M+10.6%	$159.5M-7.3%	$135.6M+59.4%	$125.1M+35.7%	$126.5M+118.5%	$172.2M+150.6%	$85.1M+9.3%
Cash & Equivalents	$17.1M-45.8%	$14.7M-83.9%	$49.7M-69.5%	$12.6M-75.8%	$31.5M-64.8%	$91.5M+75.1%	$162.8M+311.3%	$51.8M+53.3%
Short-Term Investments	$125.4M+38.2%	$121.0M+267.9%	$105.9M+1313.1%	$120.1M+303.9%	$90.7M	$32.9M+999.7%	$7.5M-71.2%	$29.7M-26.1%
Long-Term Investments	$19.4M-17.3%	$41.6M+25.6%	$42.3M	$957K	$23.4M	$33.2M	$0	$0
Total Liabilities	$14.8M+18.2%	$10.7M+6.4%	$13.1M-8.8%	$12.3M+0.4%	$12.5M+30.4%	$10.1M+3.6%	$14.3M+34.7%	$12.3M+6.8%
Current Liabilities	$13.3M+36.5%	$8.9M+27.1%	$10.9M-0.2%	$9.9M+14.7%	$9.8M+72.8%	$7.0M+27.6%	$11.0M+78.3%	$8.6M+27.6%
Non-Current Liabilities	$1.5M-46.8%	$1.8M-41.3%	$2.1M-37.0%	$2.4M-33.4%	$2.7M-30.4%	$3.1M-27.7%	$3.4M-25.1%	$3.7M-22.8%
Total Equity	$161.3M+11.7%	$181.2M+14.3%	$196.4M+17.5%	$132.3M+61.7%	$144.4M+56.9%	$158.5M+171.3%	$167.1M+144.6%	$81.8M+6.3%
Retained Earnings	-$341.9M-25.8%	-$320.2M-24.6%	-$302.4M-23.4%	-$285.1M-22.8%	-$271.9M-23.0%	-$256.9M-21.5%	-$245.0M-22.3%	-$232.2M-22.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

TARA Cash Flow Statement

TARA quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$66.1M	-$56.4M-57.4%	-$35.8M+4.7%	-$37.6M-42.0%	-$26.5M+23.3%	-$34.5M-47.4%	-$23.4M-367.1%	-$5.0M+78.4%	-$23.2M-3.9%	-$22.4M+5.6%	-$23.7M-34.8%	-$17.6M-75.8%	-$10.0M-50.1%	-$6.7M+19.2%	-$8.2M
Depreciation & Amortization	N/A	$362K+9.0%	$332K-2.6%	$341K+37.5%	$248K+112.0%	$117K+13.6%	$103K+543.8%	$16K-86.1%	$115K-22.3%	$148K+20.3%	$123K+115.8%	$57K+90.0%	$30K+11.1%	$27K-52.6%	$57K
Stock-Based Compensation	N/A	$3.8M-7.2%	$4.1M-32.3%	$6.1M-8.9%	$6.7M-35.5%	$10.4M+6.3%	$9.7M+2198.6%	$424K-87.6%	$3.4M+6.3%	$3.2M-3.5%	$3.3M+54.5%	$2.2M+371.5%	$459K+196.1%	$155K+40.9%	$110K
Capital Expenditures	N/A	$94K+49.2%	$63K+40.0%	$45K-62.5%	$120K-79.9%	$596K-32.6%	$884K+86.1%	$475K+299.2%	$119K+240.0%	$35K-87.1%	$271K+36.9%	$198K+288.2%	$51K+410.0%	$10K-85.1%	$67K
Free Cash Flow	N/A	-$56.5M-57.4%	-$35.9M+4.6%	-$37.6M-41.5%	-$26.6M+24.3%	-$35.1M-44.5%	-$24.3M-342.8%	-$5.5M+76.5%	-$23.4M-4.3%	-$22.4M+6.6%	-$24.0M-34.9%	-$17.8M-76.9%	-$10.0M-50.6%	-$6.7M+19.7%	-$8.3M
Investing Cash Flow	-$30.4M	-$139.5M-828.2%	$19.2M-63.9%	$53.1M+255.2%	$14.9M+115.2%	-$98.2M-3563.6%	$2.8M+696.8%	-$475K-102.6%	$18.4M+214.5%	-$16.1M-180.8%	$19.9M+275.8%	-$11.3M	N/A	N/A	N/A
Financing Cash Flow	$82.1M	$82.7M-40.9%	$139.9M+153797.8%	-$91K-1.1%	-$90K+60.5%	-$228K-100.1%	$189.4M+37780.2%	$500K-83.2%	$3.0M-87.0%	$23.0M+10981.3%	$208K+27.6%	$163K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$91K+1.1%	$90K-60.5%	$228K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$15.4M-25.6%	-$21.3M-45.1%	-$16.9M-82.1%	-$12.5M-47.6%	-$12.3M-59.4%	-$14.7M-41.8%	-$9.3M-7.0%	-$8.4M-28.5%
Depreciation & Amortization	$72K-26.5%	$90K+8.4%	$93K+13.4%	$88K+4.8%	$98K+18.1%	$83K0.0%	$82K-23.4%	$84K+6.3%
Stock-Based Compensation	$1.4M+53.3%	$1.4M+63.5%	N/A	$1.0M+12.5%	$903K-15.1%	$833K-32.1%	N/A	$931K-35.7%
Capital Expenditures	N/A	N/A	$24K	$4K-50.0%	$22K	$44K	$0	$8K-78.4%
Free Cash Flow	N/A	N/A	-$17.0M-82.4%	-$12.5M-47.5%	-$12.3M	-$14.8M	-$9.3M-7.0%	-$8.4M-27.9%
Investing Cash Flow	$17.8M+137.2%	-$14.7M+74.8%	-$26.9M-219.6%	-$6.5M+77.9%	-$47.7M-1720.5%	-$58.4M-352.6%	$22.5M+55.0%	-$29.4M-560.8%
Financing Cash Flow	-$26K-425.0%	$1.1M-33.9%	$81.0M-17.3%	$13K	$8K-100.0%	$1.7M+2376.3%	$97.8M	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TARA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TARA quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-257.1%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-113.4%	N/A	N/A
Return on Equity	-29.2%-2.5pp	-26.7%+32.4pp	-59.1%+5.5pp	-64.6%-35.4pp	-29.2%-12.1pp	-17.1%	N/A	-433.8%-347.6pp	-86.3%-12.0pp	-74.2%-40.5pp	-33.7%-29.7pp	-4.0%	N/A	N/A
Return on Assets	-27.4%-2.8pp	-24.6%+26.6pp	-51.2%+7.1pp	-58.2%-30.8pp	-27.4%-10.7pp	-16.7%	N/A	-88.1%-20.0pp	-68.1%-2.6pp	-65.5%-33.9pp	-31.6%-27.7pp	-3.9%+135.9pp	-139.8%	N/A
Current Ratio	14.58-1.1x	15.71+4.5x	11.17-3.8x	15.01-6.7x	21.66-36.5x	58.13+57.9x	0.23-7.3x	7.55+2.8x	4.71-3.7x	8.42-7.7x	16.12-20.1x	36.19+35.6x	0.55	N/A
Debt-to-Equity	0.070.0x	0.09-0.1x	0.160.0x	0.110.0x	0.070.0x	0.02	N/A	3.92+3.7x	0.27+0.1x	0.13+0.1x	0.070.0x	0.03	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.03	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-340.6%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-13.4%-3.1pp	-9.8%-2.3pp	N/A	-10.0%+3.7pp	-10.4%0.0pp	-7.5%+11.5pp	N/A	-13.7%-0.9pp
Return on Assets	-12.3%-2.8pp	-9.3%-2.2pp	N/A	-9.2%+2.7pp	-9.5%-0.2pp	-7.1%+9.2pp	N/A	-11.9%-0.8pp
Current Ratio	10.97-1.8x	15.69-2.3x	14.58-1.1x	13.69+3.8x	12.82-3.5x	18.03+7.5x	15.71+4.5x	9.85-1.6x
Debt-to-Equity	0.090.0x	0.060.0x	0.070.0x	0.09-0.1x	0.090.0x	0.06-0.1x	0.09-0.1x	0.150.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Protara Therapeutics, Inc. TARA	FY2025	N/A	-$57.4M	N/A	$162.8M	—
IO Biotech, Inc. IOBT	FY2025	N/A	-$95.5M	N/A	$3.5M	—
Inhibikase Therapeutics, Inc. IKT	FY2025	N/A	-$48.3M	N/A	$274.9M	—
KALA BIO, Inc. KALA	FY2025	$0	-$27.0M	N/A	$5.7M	—
Equillium, Inc. EQ	FY2025	N/A	-$22.4M	N/A	$89.4M	—
Biomea Fusion, Inc. BMEA	FY2025	N/A	-$61.8M	N/A	$102.9M	—

Where Protara Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Protara Therapeutics, Inc. profitable?

No, Protara Therapeutics, Inc. (TARA) reported a net income of -$57.4M in fiscal year 2025.

What is Protara Therapeutics, Inc.'s EBITDA?

Protara Therapeutics, Inc. (TARA) had EBITDA of -$64.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Protara Therapeutics, Inc.'s return on equity (ROE)?

Protara Therapeutics, Inc. (TARA) has a return on equity of -29.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Protara Therapeutics, Inc.'s free cash flow?

Protara Therapeutics, Inc. (TARA) recorded an outflow of $56.5M in free cash flow during fiscal year 2025. This represents a -57.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Protara Therapeutics, Inc.'s operating cash flow?

Protara Therapeutics, Inc. (TARA) recorded an outflow of $56.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Protara Therapeutics, Inc.'s total assets?

Protara Therapeutics, Inc. (TARA) had $209.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Protara Therapeutics, Inc.'s capital expenditures?

Protara Therapeutics, Inc. (TARA) invested $94K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Protara Therapeutics, Inc. spend on research and development?

Protara Therapeutics, Inc. (TARA) invested $42.6M in research and development during fiscal year 2025.

How many shares does Protara Therapeutics, Inc. have outstanding?

Protara Therapeutics, Inc. (TARA) had 54M shares outstanding as of fiscal year 2025.

What is Protara Therapeutics, Inc.'s current ratio?

Protara Therapeutics, Inc. (TARA) had a current ratio of 14.58 as of fiscal year 2025, which is generally considered healthy.

What is Protara Therapeutics, Inc.'s debt-to-equity ratio?

Protara Therapeutics, Inc. (TARA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Protara Therapeutics, Inc.'s return on assets (ROA)?

Protara Therapeutics, Inc. (TARA) had a return on assets of -27.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Protara Therapeutics, Inc.'s P/E ratio?

Protara Therapeutics, Inc. (TARA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $162.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Protara Therapeutics, Inc.'s price-to-sales ratio?

Protara Therapeutics, Inc. (TARA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $162.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Protara Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Protara Therapeutics, Inc. (TARA) held $197.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $56.4M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Protara Therapeutics, Inc.'s Piotroski F-Score?

Protara Therapeutics, Inc. (TARA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Protara Therapeutics, Inc.'s earnings high quality?

Protara Therapeutics, Inc. (TARA) reported a net loss of $57.4M while operations used $56.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.